认知障碍患者抗凝与溶栓新适应症风险:对抗淀粉样蛋白治疗的启示
该纵向队列研究纳入12373名65岁以上、无抗凝指征的成人,评估轻度认知障碍(MCI)或痴呆患者1年内新发抗凝/溶栓药物心血管适应症的风险。结果显示MCI患者任何适应症1年风险为5.7%,痴呆患者为6.7%,为抗淀粉样蛋白单抗共同处方的决策提供依据。
要点
- MCI患者1年内任何抗凝/溶栓新适应症风险为5.7%。
- 痴呆患者1年内任何抗凝/溶栓新适应症风险为6.7%。
- 房颤和卒中是最常见的新适应症,需权衡抗淀粉样蛋白单抗的出血风险。
核心结论
- 认知障碍患者中新发抗凝或溶栓药物心血管适应症的风险较高,需在抗淀粉样蛋白单抗治疗决策中权衡。
研究设计与样本
- 基于健康与退休研究(2010-2020)的纵向队列,纳入12373名65岁及以上、无既往抗凝指征且链接Medicare理赔数据的成人,认知状态分为正常、MCI或痴呆,采用Fine-Gray竞争风险模型估计1年发病率。
主要发现
- MCI患者1年风险:房颤1.7%、深静脉血栓1.2%、肺栓塞0.4%、急性心肌梗死1.2%、卒中2.0%、任何适应症5.7%。
- 痴呆患者1年风险:房颤1.7%、深静脉血栓1.8%、肺栓塞0.3%、急性心肌梗死1.0%、卒中2.4%、任何适应症6.7%。
关键数值与推荐
- MCI患者任何抗凝/溶栓新适应症1年风险为5.7%。
- 痴呆患者任何抗凝/溶栓新适应症1年风险为6.7%。
临床怎么用
- 临床医生应与MCI或痴呆患者及其家属共享决策,权衡抗淀粉样蛋白单抗治疗获益与未来可能需要抗凝/溶栓治疗的出血风险。
局限性
- 研究结果需在确认治疗资格的人群中验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Anticoagulants and thrombolytics may interact with anti-amyloid monoclonal antibodies (mAbs) to increase intracranial hemorrhage risk, so expert guidance recommends against their co-prescription. We aimed to estimate how many people with mild cognitive impairment (MCI) or dementia develop a new cardiovascular indication for anticoagulant and thrombolytic drugs. METHODS: In a longitudinal cohort of adults aged 65 years or older from the Health and Retirement Study (2010-2020) with linked Medicare claims and no previous indication for anticoagulants, cognition was categorized as normal, MCI, or dementia. We fit separate Fine-Gray survival models accounting for competing risk of death to estimate 1-year incidence of atrial fibrillation (AF), deep vein thrombosis (DVT), pulmonary embolism (PE), acute myocardial infarction (AMI), and stroke. RESULTS: Among 12,373 participants (mean age 73 years, 59% female), the 1-year risk in those with MCI was 1.7% for AF, 1.2% for DVT, 0.4% for PE, 1.2% for AMI, 2.0% for stroke, and 5.7% for any indication. In those with dementia, the 1-year risk was 1.7% for AF, 1.8% for DVT, 0.3% for PE, 1.0% for AMI, 2.4% for stroke, and 6.7% for any indication. DISCUSSION: Our findings inform shared decision making about the tradeoffs of anti-amyloid mAbs but should be validated in populations with confirmed treatment eligibility.
引用
- Parks AL, Lykken JM, Rieu-Werden ML, et al. Risk of New Indications for Anticoagulants and Thrombolytics in People With Cognitive Impairment: Implications for Anti-Amyloid Therapy. Neurology. 2025. PMID: 41461060. doi:10.1212/WNL.0000000000214489
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。